Early-phase amyloid PET reproduces metabolic signatures of cognitive decline in Parkinson's disease.
William W T AyeMegan R StarkKyla-Louise HorneLeslie LivingstonSophie GrenfellDaniel J MyallToni L PitcherMustafa M AlmuqbelRoss J KeenanWassilios G MeissnerJohn C Dalrymple-AlfordTim J AndersonCampbell Le HeronTracy R MelzerPublished in: Alzheimer's & dementia (Amsterdam, Netherlands) (2024)
Images taken at amyloid beta (Aβ) positron emission tomography tracer injection may reflect brain perfusion and metabolism.Parkinson's disease (PD) is a predominantly amyloid-negative condition.Early-phase florbetaben (eFBB) in PD was associated with cognitive performance.eFBB uptake reflects hypometabolism-related cognitive decline in PD.eFBB correlated with arterial spin labeling magnetic resonance imaging measured cerebral perfusion.eFBB distinguished dementia from normal cognition and mild cognitive impairment.Findings were independent of late-phase Aβ burden.Thus, eFBB may serve as a surrogate measure for brain metabolism/perfusion.
Keyphrases
- mild cognitive impairment
- cognitive decline
- positron emission tomography
- computed tomography
- contrast enhanced
- magnetic resonance imaging
- pet imaging
- pet ct
- white matter
- resting state
- cerebral ischemia
- genome wide
- convolutional neural network
- room temperature
- optical coherence tomography
- magnetic resonance
- diffusion weighted imaging
- african american
- cerebral blood flow
- drug induced
- transition metal